448
Participants
Start Date
August 31, 2005
Primary Completion Date
August 31, 2006
Study Completion Date
August 31, 2006
Lapaquistat acetate and atorvastatin
Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Lapaquistat acetate and atorvastatin
Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Atorvastatin
Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Birmingham
Northport
Sierra Vista
Tucson
Jonesboro
Searcy
Anaheim
Carmichael
Chula Vista
Escondido
Pismo Beach
Santa Rosa
Golden
Waterbury
Clearwater
Daytona Beach
Hollywood
Jacksonville
Jupiter
Kissimmee
Miami
New Port Richey
Ocala
Pembroke Pines
West Palm Beach
Honolulu
Arlington Heights
Chicago
Peoria
Bloomington
Evansville
Indianapolis
Waterloo
Arkansas City
Kansas City
Overland Park
Wichita
Louisville
Auburn
Livonia
Edina
Omaha
Las Vegas
Edison
Margate City
New Hyde Park
Rochester
Syracuse
Hickory
Raleigh
Statesville
Winston-Salem
Cincinnati
Tulsa
Medford
Portland
Allentown
Altoona
Downingtown
Sellerville
Tipton
Warwick
Charleston
Mt. Pleasant
Simpsonville
Chattanooga
Morristown
Corpus Christi
Dallas
Euless
San Antonio
The Colony
Ogden
Salt Lake City
Norfolk
Richmond
Renton
Madison
Lead Sponsor
Takeda
INDUSTRY